Skip to main content Accessibility help
×
Home

Effects of Pamidronate on Dental Enamel Formation Assessed by Light Microscopy, Energy-Dispersive X-Ray Analysis, Scanning Electron Microscopy, and Microhardness Testing

  • Ana P. Soares (a1), Renan F. do Espírito Santo (a2), Sérgio R. P. Line (a3), Maria das G. F. Pinto (a4), Pablo de M. Santos (a5), Maria Betania P. Toralles (a6) and Alexandre R. do Espírito Santo (a6)...

Abstract

The aim of the present work was to investigate birefringence and morphology of the secretory-stage enamel organic extracellular matrix (EOECM), and structural and mechanical properties of mature enamel of upper incisors from adult rats that had been treated with pamidronate disodium (0.5 mg/kg/week for 56 days), using transmitted polarizing and bright-field light microscopies (TPLM and BFLM), energy-dispersive X-ray (EDX) analysis, scanning electron microscopy (SEM) and microhardness testing. BFLM showed no morphological changes of the EOECM in pamidronate and control groups, but TPLM revealed a statistically significant reduction in optical retardation values of birefringence brightness of pamidronate-treated rats when compared with control animals (p<0.01). EDX analysis showed that pamidronate-induced statistically significant decrease in phosphorus’ quantity in outer mature enamel (p<0.01) and an increase in the calcium/phosphorus ratio in that structure (p<0.05). Pamidronate did not induce ultra-structural alterations in mature enamel as revealed by SEM and did not cause a reduction in its microhardness (p>0.05). The present study indicates that pamidronate can affect birefringence of the secretory-stage EOECM, which does not seem to be associated with significant changes in morphological and/or mechanical properties of mature enamel.

Copyright

Corresponding author

* Corresponding author. arespiritosanto@ufba.br

References

Hide All
August, K.J., Dalton, A., Katzenstein, H.M., George, B., Olson, T.A., Wasilewski-Masker, K. & Rapkin, L.B. (2011). The use of zoledronic acid in pediatric cancer patients. Pediatr Blood Cancer 56, 610614.
Bachrach, L.K. & Ward, L.M. (2009). Clinical review 1: Bisphosphonate use in childhood osteoporosis. J Clin Endocrinol Metab 94, 400409.
Bajpai, A., Kabra, M., Gupta, N., Sharda, S. & Ghosh, M. (2007). Intravenous pamidronate therapy in osteogenesis imperfecta: Response to treatment and factors influencing outcome. J Pediatr Orthop 27, 225227.
Baroncelli, G.I. & Bertelloni, S. (2014). The use of bisphosphonates in pediatrics. Horm Res Paediatr 82, 290302.
Barros, E.R., Saraiva, G.L., de Oliveira, T.P. & Lazaretti-Castro, M. (2012). Safety and efficacy of a 1-year treatment with zoledronic acid compared with pamidronate in children with osteogenesis imperfecta. J Pediatr Endocrinol Metab 25, 485491.
Bartlett, J.D. (2013). Dental enamel development: Proteinases and their enamel matrix substrates. ISRN Dent 2013, PMC3789414.
Bishop, N., Adami, S., Ahmed, S.F., Antón, J., Arundel, P., Burren, C.P., Devogelaer, J.P., Hangartner, T., Hosszú, E., Lane, J.M., Lorenc, R., Mäkitie, O., Munns, C.F., Paredes, A., Pavlov, H., Plotkin, H., Raggio, C.L., Reyes, M.L., Schoenau, E., Semler, O., Sillence, D.O. & Steiner, R.D. (2013). Risedronate in children with osteogenesis imperfecta: A randomised, double-blind, placebo-controlled trial. Lancet 382, 14241432.
Castillo, H. & Samson-Fang, L. & American Academy for Cerebral Palsy and Developmental Medicine Treatment Outcomes Committee Review Panel (2009). Effects of bisphosphonates in children with osteogenesis imperfecta: An AACPDM systematic review. Dev Med Child Neurol 51, 1729.
Chilbule, S.K. & Madhuri, V. (2012). Complications of pamidronate therapy in paediatric osteoporosis. J Child Orthop 6, 3743.
Cremers, S. & Papapoulos, S. (2011). Pharmacology of bisphosphonates. Bone 49, 4249.
do Espírito Santo, A.R., Frozoni, M.R., Ramos-Perez, F.M., Novaes, P.D. & Line, S.R. (2010). Birefringence of the secretory-stage enamel organic extracellular matrix from rats submitted to successive injections of bisphosphonates. Connect Tissue Res 51, 208215.
do Espírito Santo, A.R., Novaes, P.D. & Line, S.R. (2006). Anisotropic properties of the enamel organic extracellular matrix. Eur J Oral Sci 114(Suppl 1), 333337.
Dwan, K., Phillipi, C.A., Steiner, R.D. & Basel, D. (2014). Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database Syst Rev 7, CD005088. doi: 10.1002/14651858.CD005088.pub3.
Espírito Santo, A.R., Bartlett, J.D., Gibson, C.W., Li, Y., Kulkarni, A.B. & Line, S.R. (2007). Amelogenin- and enamelysin (Mmp-20)-deficient mice display altered birefringence in the secretory-stage enamel organic extracellular matrix. Connect Tissue Res 48, 3945.
Fejerskov, O., Josephsen, K. & Weile, V. (1990). The effect of a single dose of 1-hydroxyethylidene-1, 1-bisphosphonate (HEBP) on secretory ameloblasts and enamel formation in rat incisors. J Biol Buccale 18, 339354.
Fleisch, H. (1993). Prospective use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab 76, 13971398.
Fleisch, H. (1997). Bisphosphonates: Mechanisms of action and clinical use in osteoporosis—an update. Horm Metab Res 29, 145150.
Fouda, N., Caracatsanis, M. & Hammarstrom, L. (1989). Developmental disturbances of the rat molar induced by two diphosphonates. Adv Dent Res 3, 234240.
Fouda, N., Caracatsanis, M., Kut, I.A. & Hammarstrom, L. (1991). Mineralization disturbances of the developing rat molar induced by mono- and bisphosphonates. J Biol Buccale 19, 106115.
Fuangtharnthip, P., Yamada, Y., Takagi, Y. & Ohya, K. (2000). Autoradiographic investigation of the effect of 1-hydroxyethylidene, 1-bisphosphonate on matrix protein synthesis and secretion by secretory ameloblasts in rat incisors. Arch Oral Biol 45, 495506.
Glorieux, F.H., Bishop, N.J., Plotkin, H., Chabot, G., Lanoue, G. & Travers, R. (1998). Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 339, 947952.
Heikkilä, P., Teronen, O., Moilanen, M., Konttinen, Y.T., Hanemaaijer, R., Laitinen, M., Maisi, P., van der Pluijm, G., Bartlett, J.D., Salo, T. & Sorsa, T. (2002). Bisphosphonates inhibit stromelysin-1 (MMP-3), matrix metalloelastase (MMP-12), collagenase-3 (MMP-13) and enamelysin (MMP-20), but not urokinase-type plasminogen activator, and diminish invasion and migration of human malignant and endothelial cell lines. Anticancer Drugs 13, 245254.
Hiraga, T., Ninomiya, T., Hosoya, A. & Nakamura, H. (2010). Administration of the bisphosphonate zoledronic acid during tooth development inhibits tooth eruption and formation and induces dental abnormalities in rats. Calcif Tissue Int 86, 502510.
Iwai, T., Isomatsu, Y., Iwamoto, M. & Tohnai, I. (2013). Bisphosphonate-related enamel hypoplasia in a child with idiopathic arterial calcification of infancy. Br J Oral Maxillofac Surg 51, e186e187.
Josephsen, K., Fejerskov, O., Baelum, V. & Weile, V. (1990). The effect of a single dose of 1-hydroxyethylidene-1,1-bisphosphonate (HEBP) on presecretory ameloblast differentiation in rat incisors. J Biol Buccale 18, 321337.
Kamoun-Goldrat, A., Ginisty, D. & Le Merrer, M. (2008). Effects of bisphosphonates on tooth eruption in children with osteogenesis imperfecta. Eur J Oral Sci 116, 195198.
Kitaoka, T., Namba, N., Miura, K., Kubota, T., Ohata, Y., Fujiwara, M., Hirai, H., Yamamoto, T. & Ozono, K. (2011). Decrease in serum FGF23 levels after intravenous infusion of pamidronate in patients with osteogenesis imperfecta. J Bone Miner Metab 29, 598605.
Maasalu, K., Haviko, T. & Martson, A. (2003). Treatment of children with osteogenesis imperfecta in Estonia. Acta Paediatr 92, 452455.
Massa, L.F., Bradaschia-Correa, V. & Arana-Chavez, V.E. (2006). Immunocytochemical study of amelogenin deposition during the early odontogenesis of molars in alendronate-treated newborn rats. J Histochem Cytochem 54, 713725.
Modesto, A., Klein, O., Tenuta, L.M., Gerlach, R.F. & Vieira, A.R. (2013). Summary of the IADR Cariology Research, Craniofacial Biology, and Mineralized Tissue Groups Symposium, Iguaçu Falls, Brazil, June 2012: Gene-environment interactions and epigenetics in oral diseases: enamel formation and its clinical impact on tooth defects, caries, and erosion. Dent 3000 1, PMC4225817.
Nelson-Filho, P., Lucisano, M.P., da Silva, R.A., da Silva, R.S., Serra, M.C., Gerlach, R.F., Neto, F.C., Carneiro, Z.A., Zamarioli, A., Morse, L. & Battaglino, R. (2012). Systemically alendronate was incorporated into dental tissues but did not cause morphological or mechanical changes in rats teeth. Microsc Res Tech 75, 12651271.
Phillipi, C.A., Remmington, T. & Steiner, R.D. (2008). Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database Syst Rev 4, CD005088. doi: 10.1002/14651858.CD005088.pub2.
Plotkin, H., Rauch, F., Bishop, N.J., Montpetit, K., Ruck-Gibis, J., Travers, R. & Glorieux, F.H. (2000). Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. J Clin Endocrinol Metab 85, 18461850.
Rodan, G.A. & Fleisch, H.A. (1996). Bisphosphonates: Mechanisms of action. J Clin Invest 97, 26922696.
Russell, R.G. (2011). Bisphosphonates: The first 40 years. Bone 49, 219.
Simmelink, J.W. (1987). Ultrastructural effects of diphosphonates on dental enamel. Adv Dent Res 1, 356365.
Smith, C.E. & Nanci, A. (1989). A method for sampling the stages of amelogenesis on mandibular rat incisors using the molars as a reference for dissection. Anat Rec 225, 257266.
Sukumar, S.P., Balachandran, K., Sahoo, J.P. & Kamalanathan, S. (2013). Zebra lines in osteogenesis imperfecta on bisphosphonate therapy. BMJ Case Rep 2013, 12.
Thesleff, I., Vaahtokari, A., Kettunen, P. & Aberg, T. (1995). Epithelial-mesenchymal signaling during tooth development. Connect Tissue Res 32, 915.
van Beek, E.R., Lowik, C. & Papapoulos, S. (2002). Bisphosphonates suppress bone resorption by a direct effect on early osteoclast precursors without affecting the osteoclastogenic capacity of osteogenic cells: The role of protein geranylgeranylation in the action of nitrogen-containing bisphosphonates on osteoclast precursors. Bone 30, 6470.
van Beek, E.R., Pieterman, E., Cohen, L., Lowik, C. & Papapoulos, S. (1999). Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive pontencies in vitro and in vivo . Biochem Biophys Res Commun 263, 754758.
Wakamatsu, H. (1991). A study of the effects of successive injections of 1-hydroxyethylidene-1, 1-bisphosphonate (HEBP) on the enamel formation of rat incisor. Jpn J Oral Biol 33, 8296.
Ward, L.M., Rauch, F., Whyte, M.P., D’Astous, J., Gates, P.E., Grogan, D., Lester, E.L., McCall, R.E., Pressly, T.A., Sanders, J.O., Smith, P.A., Steiner, R.D., Sullivan, E., Tyerman, G., Smith-Wright, D.L., Verbruggen, N., Heyden, N., Lombardi, A. & Glorieux, F.H. (2011). Alendronate for the treatment of pediatric osteogenesis imperfecta: A randomized placebo-controlled study. J Clin Endocrinol Metab 96, 355364.
Weile, V., Josephsen, K. & Fejerskov, O. (1990). Effects of single doses of 1-hydroxyethylidene-1,1-bisphosphonate on the mineralizing front of rat incisor enamel: A microradiographic and scanning electron microscopic study. Arch Oral Biol 35, 857867.
Weile, V., Josephsen, K. & Fejerskov, O. (1993). Scanning electron microscopy of final enamel formation in rat mandibular incisors following single injections of 1-hydroxyethylidene-1,1-bisphosphonate. Calcif Tissue Int 52, 318324.
Yamada, Y., Fuangtharnthip, P., Tamura, Y., Takagi, Y. & Ohya, K. (2000). Gene expression and immunolocalization of amelogenin in enamel hypoplasia induced by successive injections of bisphosphonate in rat incisors. Arch Oral Biol 45, 207215.

Keywords

Effects of Pamidronate on Dental Enamel Formation Assessed by Light Microscopy, Energy-Dispersive X-Ray Analysis, Scanning Electron Microscopy, and Microhardness Testing

  • Ana P. Soares (a1), Renan F. do Espírito Santo (a2), Sérgio R. P. Line (a3), Maria das G. F. Pinto (a4), Pablo de M. Santos (a5), Maria Betania P. Toralles (a6) and Alexandre R. do Espírito Santo (a6)...

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed